Review the Metabolism and Function of Sphingolipids and Glycosphingolipids

Total Page:16

File Type:pdf, Size:1020Kb

Review the Metabolism and Function of Sphingolipids and Glycosphingolipids Cell. Mol. Life Sci. 64 (2007) 2270 – 2284 1420-682X/07/172270-15 Cellular and Molecular Life Sciences DOI 10.1007/s00018-007-7076-0 Birkhuser Verlag, Basel, 2007 Review The metabolism and function of sphingolipids and glycosphingolipids S. Lahiri and A. H. Futerman* Department of Biological Chemistry, Weizmann Institute of Science, Rehovot 76100 (Israel), Fax : +9728-9344112, e-mail: [email protected] Received 13 February 2007; received after revision 19 April 2007; accepted 26 April 2007 Online First 11 June 2007 Abstract. Sphingolipids and glycosphingolipids are between them. We then discuss some roles of sphin- emerging as major players in many facets of cell golipids in cell physiology, particularly those of physiology and pathophysiology. We now present an ceramide and sphingosine-1-phosphate, and mention overview of sphingolipid biochemistry and physiol- current views about how these lipids act in signal ogy, followed by a brief presentation of recent transduction pathways. We end with a discussion of advances in translational research related to sphingo- sphingolipids and glycosphingolipids in the etiology lipids. In discussing sphingolipid biochemistry, we and pathology of a number of diseases, such as cancer, focus on the structure of sphingolipids, and their immunity, cystic fibrosis, emphysema, diabetes, and biosynthetic pathways – the recent identification of sepsis, areas in which sphingolipids are beginning to most of the enzymes in this pathway has led to take a central position, even though many of the significant advances and better characterization of a details remain to be elucidated. number of the biosynthetic steps, and the relationship Keywords. Sphingolipid, glycosphingolipid, ceramide, sphingosine-1-phosphate, apoptosis, cancer. Introduction lipid bilayers and their roles in signaling, and over the past few years in lipidomics, as well as advances in All eukaryotic cells are surrounded by a membrane understanding the biophysical properties of lipids, has composed of a lipid bilayer, whose chemical nature led to a major rethink of the structural and functional and essential role in cell permeability were first complexity of lipid bilayers and the role that specific proposed around a hundred years ago. Today it is lipids play in defined biological events. Clearly, the known that there are three major classes of lipids in classical and simplistic cartoon of a membrane, eukaryotic cell membranes, namely glycerolipids, containing a hydrophilic head group (often depicted sphingolipids (SLs), and sterols, whose biochemical as a ball) with two fatty acyl chains attached (depicted and biophysical properties vary considerably and as two sticks) does not do justice to the intricacies of impact upon their function. Progress over the past bilayer structure. Indeed, the number of possible lipid two or three decades in elucidating the components of species, as well as the number observed experimen- tally to date (see for instance Lipid Maps at http:// www.lipidmaps.org) implies previously unsuspected * Corresponding author. complexity [1]. Moreover, since many of these lipids Cell. Mol. Life Sci. Vol. 64, 2007 Review Article 2271 Figure 1. The structure of SLs and GSLs. S1P, sphingosine 1- phosphate; SM, sphingomyelin; GlcCer, glucosyl ceramide. The inset shows the numbering of the first five carbon atoms of the sphingoid long chain base. The sphingoid base is in the D-erythro (2S,3R) conformation. are bioactive and turn over in signaling pathways, SL structure combinatorial aspects of lipid structure and function are bound to play increasingly important roles in The backbone of all SLs, and the compound from models of membrane structure. which SLs derive their name, is the sphingoid long- Having briefly introduced the enormous combinato- chain base, the most common of which are sphinga- rial diversity of lipids, we will focus in this review on nine and sphingosine (Fig. 1). Sphinganine differs one particular class of lipids, the SLs, and their from sphingosine inasmuch as the latter contains a glycosylated derivatives, the glycosphingolipids trans 4–5 double bond, which is essential for some of (GSLs). Our rationale is that a reductionist approach the bioactive roles in which sphingosine-based SLs are to understanding lipid complexity is the most reason- involved. A number of other sphingoid long-chain able lead-in, and a required first step, to appreciate the bases exist, such as phytosphingosine (4-hydroxy- complexity of lipid bilayers and how this complexity sphinganine) with a hydroxyl group at C-4, and the less impacts upon their biological functions. Thus, we will common methylsphingosine, which has a methyl first describe the structure and biosynthesis of SLs, group at C-15, and sphingoid bases containing 20 and then discuss their major cellular functions, partic- carbon atoms which are found at high levels in brain ularly those of two important bioactive SLs, ceramide gangliosides. In rare cases, sphingoid bases containing and sphingosine-1-phophate (S1P). We will then 14 carbons have been described [2]. discuss some aspects of translational research con- Ceramide, the simplest SL, consists of a sphingoid cerning SLs and GSLs; this latter issue is rapidly base to which a fatty acid is attached at C-2 via N- developing and moving toward clinical manipulation acylation (Fig. 1). SLs usually contain saturated fatty of SL levels as a novel therapeutic approach in human acids of varying chain length and degree of hydrox- diseases. ylation, although monounsaturated fatty acids, partic- ularly with very long chains, can also be found in SLs [3]. Ceramide is the backbone of all complex SLs, which are formed by attachment of different head groups at C-1. Attachment of phosphorylcholine 2272 S. Lahiri and A. H. Futerman Sphingolipids and glycosphingolipids forms sphingomyelin (SM), and attachment of glucose proteins encoded by these genes are integral mem- or galactose is the first step in the formation of GSLs brane proteins that span the membrane lipid bilayer (Fig. 1). The GSLs are the most structurally diverse multiple times. Each member of the family has a class of complex SLs, and are normally classified as unique tissue distribution and uses a unique subset of acidic or neutral. More than 500 different carbohy- acyl CoAs for dihydroceramide synthesis [12]. Ce- drate structures have been described in GSLs [4, 5], ramide is subsequently formed by dihydroceramide with the main sugars being glucose, galactose, fucose, desaturase/reductase, which inserts a trans 4–5 double N-acetylglucosamine (GlcNAc), N-acetylgalactosa- bond. All of these reactions occur at the cytosolic mine (GalNAc) and sialic acid (N-acetylneuraminic leaflet of the ER [13–15]. acid). GSLs containing sialic acid are the major class Ceramide is the key hub in the SL biosynthetic of acidic GSLs, but other acidic GSLs exist, such as pathway, and is the precursor of at least five different those that contain glucuronic acid or sulfatides [6]. products (Fig. 2): The complexity of SLs is thus based on three structural a) Ceramide is glycosylated to galactosylceramide components, the sphingoid base, the fatty acid, and the (GalCer) at the lumenal leaflet of the ER by the head group. The reason for such a variety of SL transfer of galactose from a UDP-galactose donor structures is not known, but implies an as-yet un- [16]. known degree of functional complexity. It is not clear b) Ceramide can be phosphorylated by ceramide whether each particular SL or GSL structure has a kinase to produce ceramide-1-phosphate. The subcel- unique role of its own, or whether the roles of SLs and lular localization of this enzyme is unresolved, and has GSLs are defined by their combinatorial patterns at been suggested to be the PM [17, 18], Golgi apparatus any one time and their distribution (or segregation) [19], and the cytoplasm [18]. over the plasma membrane (PM) surface. In addition, c) Ceramide can be deacylated to sphingosine and although the basic pathways of SL synthesis have been free fatty acid by ceramidases, of which various forms established (see below), little is known about how are known, acting at either neutral, alkaline, or acidic these pathways are regulated at the transcriptional, pH. Neutral ceramidase is located at the PM [20, 21], translational or post-translational levels, each of acid ceramidase is lysosomal [22], and the alkaline which could determine the SL pattern of a cell or ceramidase is located at the ER/Golgi complex [23– tissue at any one time. 25]. Ceramidase activity has also been reported in mitochondria [21]. d) The synthesis of SM from ceramide occurs at the SL metabolism and intracellular transport lumenal leaflet of the Golgi apparatus [26, 27] by transfer of phosphorylcholine from phosphatidylcho- The biochemical pathways of SL metabolism are well line (PC) to ceramide, with diacylglycerol formed as a described [7, 8], and the intracellular sites of synthesis by-product [28]. Recently two SM synthases (SMs) and degradation, in the endoplasmic reticulum (ER)/ have been identified; SMS1 is located at the Golgi Golgi apparatus and lysosomes, respectively, have apparatus, and SMS2 at the PM [29, 30]. Since been characterized extensively over the past couple of ceramide is synthesized in the ER, a mechanism decades [7, 9]. As might be expected from the lipidic must exist for transferring ceramide to the Golgi nature of their substrates, the enzymes in the SL apparatus for its metabolism to SM. It was earlier biosynthetic pathway are integral membrane proteins assumed that vesicular transport would be responsible that span the membrane bilayer one or multiple times; for ceramide transfer; however, a ceramide transport in contrast, many of the lysosomal hydrolases involved protein, CERT, which transfers ceramides of relative- in SL degradation are peripheral membrane proteins ly short acyl chain length (C16–20) from the ER that require the presence of activating proteins for specifically for SM synthesis in the Golgi apparatus maximal activity in vivo [7, 10]. [31], has recently been discovered and is absolutely SL synthesis begins with the condensation of serine required for SM synthesis [32] by SMS1.
Recommended publications
  • GM2 Gangliosidoses: Clinical Features, Pathophysiological Aspects, and Current Therapies
    International Journal of Molecular Sciences Review GM2 Gangliosidoses: Clinical Features, Pathophysiological Aspects, and Current Therapies Andrés Felipe Leal 1 , Eliana Benincore-Flórez 1, Daniela Solano-Galarza 1, Rafael Guillermo Garzón Jaramillo 1 , Olga Yaneth Echeverri-Peña 1, Diego A. Suarez 1,2, Carlos Javier Alméciga-Díaz 1,* and Angela Johana Espejo-Mojica 1,* 1 Institute for the Study of Inborn Errors of Metabolism, Faculty of Science, Pontificia Universidad Javeriana, Bogotá 110231, Colombia; [email protected] (A.F.L.); [email protected] (E.B.-F.); [email protected] (D.S.-G.); [email protected] (R.G.G.J.); [email protected] (O.Y.E.-P.); [email protected] (D.A.S.) 2 Faculty of Medicine, Universidad Nacional de Colombia, Bogotá 110231, Colombia * Correspondence: [email protected] (C.J.A.-D.); [email protected] (A.J.E.-M.); Tel.: +57-1-3208320 (ext. 4140) (C.J.A.-D.); +57-1-3208320 (ext. 4099) (A.J.E.-M.) Received: 6 July 2020; Accepted: 7 August 2020; Published: 27 August 2020 Abstract: GM2 gangliosidoses are a group of pathologies characterized by GM2 ganglioside accumulation into the lysosome due to mutations on the genes encoding for the β-hexosaminidases subunits or the GM2 activator protein. Three GM2 gangliosidoses have been described: Tay–Sachs disease, Sandhoff disease, and the AB variant. Central nervous system dysfunction is the main characteristic of GM2 gangliosidoses patients that include neurodevelopment alterations, neuroinflammation, and neuronal apoptosis. Currently, there is not approved therapy for GM2 gangliosidoses, but different therapeutic strategies have been studied including hematopoietic stem cell transplantation, enzyme replacement therapy, substrate reduction therapy, pharmacological chaperones, and gene therapy.
    [Show full text]
  • NEW--Npf-MASTER LIST.Xlsx
    National Performance Formulary Prior Approval List As of: April 21, 2021 Helpful Tip: To search for a specific drug, use the find feature (Ctrl + F) Trade Name Chemical/Biological Name Class Prior Authorization Program FUSILEV LEVOLEUCOVORIN CALCIUM ADJUNCTIVE AGENTS UNCLASSIFIED DRUG PRODUCTS KHAPZORY LEVOLEUCOVORIN ADJUNCTIVE AGENTS UNCLASSIFIED DRUG PRODUCTS LEVOLEUCOVORIN CALCIUM LEVOLEUCOVORIN CALCIUM ADJUNCTIVE AGENTS UNCLASSIFIED DRUG PRODUCTS VISTOGARD URIDINE TRIACETATE ADJUNCTIVE AGENTS UNCLASSIFIED DRUG PRODUCTS ACTHAR CORTICOTROPIN ADRENAL HORMONES HORMONES BELRAPZO BENDAMUSTINE HCL ALKYLATING AGENTS ANTINEOPLASTICS BENDAMUSTINE HCL BENDAMUSTINE HCL ALKYLATING AGENTS ANTINEOPLASTICS BENDEKA BENDAMUSTINE HCL ALKYLATING AGENTS ANTINEOPLASTICS PEPAXTO MELPHALAN FLUFENAMIDE INJECTION FOR INTRAVENOUS INFUSION ALKYLATING AGENTS ANTINEOPLASTICS TREANDA BENDAMUSTINE HCL ALKYLATING AGENTS ANTINEOPLASTICS DAW (DISPENSE AS WRITTEN) ALL CUSTOM HOMOZYGOUS FAMILIAL EVKEEZA EVINACUMAB‐DGNB INJECTION ANGIOPOIETIN LIKE 3 INHIBITOR HYPERCHOLESESTEROLEMIA BELVIQ LORCASERIN HCL ANOREXIANTS ANTI‐OBESITY DRUGS BELVIQ XR LORCASERIN HCL ANOREXIANTS ANTI‐OBESITY DRUGS CONTRAVE ER NALTREXONE HCL/BUPROPION HCL ANOREXIANTS ANTI‐OBESITY DRUGS DIETHYLPROPION HCL DIETHYLPROPION HCL ANOREXIANTS ANTI‐OBESITY DRUGS DIETHYLPROPION HCL ER DIETHYLPROPION HCL ANOREXIANTS ANTI‐OBESITY DRUGS LOMAIRA PHENTERMINE HCL ANOREXIANTS ANTI‐OBESITY DRUGS PHENDIMETRAZINE TARTRATE PHENDIMETRAZINE TARTRATE ANOREXIANTS ANTI‐OBESITY DRUGS QSYMIA PHENTERMINE/TOPIRAMATE ANOREXIANTS
    [Show full text]
  • Monitoring Immune Responses in Neuroblastoma Patients During Therapy
    cancers Review Monitoring Immune Responses in Neuroblastoma Patients during Therapy 1, 1, 1 1,2, Celina L. Szanto y, Annelisa M. Cornel y , Saskia V. Vijver and Stefan Nierkens * 1 Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, 3584 CX Utrecht, The Netherlands; [email protected] (C.L.S.); [email protected] (A.M.C.); [email protected] (S.V.V.) 2 Princess Máxima Center for Pediatric Oncology, Utrecht University, 3584 CS Utrecht, The Netherlands * Correspondence: [email protected] These authors contributed equally to this work. y Received: 29 December 2019; Accepted: 18 February 2020; Published: 24 February 2020 Abstract: Neuroblastoma (NBL) is the most common extracranial solid tumor in childhood. Despite intense treatment, children with this high-risk disease have a poor prognosis. Immunotherapy showed a significant improvement in event-free survival in high-risk NBL patients receiving chimeric anti-GD2 in combination with cytokines and isotretinoin after myeloablative consolidation therapy. However, response to immunotherapy varies widely, and often therapy is stopped due to severe toxicities. Objective markers that help to predict which patients will respond or develop toxicity to a certain treatment are lacking. Immunotherapy guided via immune monitoring protocols will help to identify responders as early as possible, to decipher the immune response at play, and to adjust or develop new treatment strategies. In this review, we summarize recent studies investigating frequency and phenotype of immune cells in NBL patients prior and during current treatment protocols and highlight how these findings are related to clinical outcome.
    [Show full text]
  • Rxoutlook® 4Th Quarter 2020
    ® RxOutlook 4th Quarter 2020 optum.com/optumrx a RxOutlook 4th Quarter 2020 While COVID-19 vaccines draw most attention, multiple “firsts” are expected from the pipeline in 1Q:2021 Great attention is being given to pipeline drugs that are being rapidly developed for the treatment or prevention of SARS- CoV-19 (COVID-19) infection, particularly two vaccines that are likely to receive emergency use authorization (EUA) from the Food and Drug Administration (FDA) in the near future. Earlier this year, FDA issued a Guidance for Industry that indicated the FDA expected any vaccine for COVID-19 to have at least 50% efficacy in preventing COVID-19. In November, two manufacturers, Pfizer and Moderna, released top-line results from interim analyses of their investigational COVID-19 vaccines. Pfizer stated their vaccine, BNT162b2 had demonstrated > 90% efficacy. Several days later, Moderna stated their vaccine, mRNA-1273, had demonstrated 94% efficacy. Many unknowns still exist, such as the durability of response, vaccine performance in vulnerable sub-populations, safety, and tolerability in the short and long term. Considering the first U.S. case of COVID-19 was detected less than 12 months ago, the fact that two vaccines have far exceeded the FDA’s guidance and are poised to earn EUA clearance, is remarkable. If the final data indicates a positive risk vs. benefit profile and supports final FDA clearance, there may be lessons from this accelerated development timeline that could be applied to the larger drug development pipeline in the future. Meanwhile, drug development in other areas continues. In this edition of RxOutlook, we highlight 12 key pipeline drugs with potential to launch by the end of the first quarter of 2021.
    [Show full text]
  • Antitumor Efficacy of Anti-GD2 Igg1 Is Enhanced by Fc Glyco-Engineering
    Author Manuscript Published OnlineFirst on May 16, 2016; DOI: 10.1158/2326-6066.CIR-15-0221 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Antitumor efficacy of anti-GD2 IgG1 is enhanced by Fc glyco-engineering Hong Xu, Hongfen Guo, Irene Y. Cheung, Nai-Kong V. Cheung Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA Running title: Fc glyco-enhanced IgG1 using GnT1–/– CHO cells Key words: hu3F8, GD2, GnT1, glyco-enhanced, mannose, fucose Financial support: This study was supported, in part, by grants from the Band of Parents, Arms Wide Open Cancer Foundation, Kids Walk for Kids with Cancer NYC, Robert Steel Foundation, and Enid A. Haupt Chair Endowment Fund. Technical service provided by the MSK Small-Animal Imaging Core Facility was supported in part by the NIH Cancer Center Support Grant P30 CA008748. Correspondence to: Nai-Kong Cheung, MD PhD, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065. Tel No. 646- 888-2313; Fax No. 646-422-0452; E-mail: [email protected] Disclosure: NK Cheung and H Xu were named as co-inventors on a patent application for humanized anti-GD2 antibodies hu3F8 filed by Memorial Sloan Kettering Cancer Center. NK Cheung and MSKCC have financial interest in hu3F8 which is licensed to YmAbs Inc. The other authors declare they have no competing interests as defined by the Journal, or other interests that might be perceived to influence the results and discussion reported in this paper.
    [Show full text]
  • National/Preferred 4 Tier Split
    Preferred Drug List Drug list — Five Tier Drug Plan Your prescription benefit comes with a drug list, which is also called a formulary. This list is made up of brand-name and generic prescription drugs approved by the U.S. Food & Drug Administration (FDA). We’re here to help. If you are a current Anthem member with questions about your pharmacy benefits, we're here to help. Just call us at the Member Services number on your ID card. The product names to which this formulary applies are shown below. $5/$15/$25/$45/30% to $250 $5/$20/$40/$60/30% to $250 Rx ded $150 $5/$15/$30/$50/30% to $250 $5/$20/$40/$75/30% to $250 $5/$15/$40/$60/30% to $250 $5/$20/$40/$75/30% to $250 Rx ded $250 $5/$15/$50/$65/30% to $250 after deductible $5/$20/$50/$65/30% to $250 Rx ded $500 $5/$20/$30/$50/30% to $250 $5/$20/$50/$70/30% to $250 $5/$20/$40/$60/30% to $250 $5/$20/$50/$70/30% to $250 after deductible Here are a few things to remember: o You can view and search our current drug lists when you visit anthem.com/ca/pharmacyinformation. Please note: The formulary is subject to change and all previous versions of the formulary are no longer in effect. o Additional tools and resources are available for current Anthem members to view the most up-to-date list of drugs for your plan - including drugs that have been added, generic drugs and more – by logging in at anthem.com/ca/pharmacyinformation.
    [Show full text]
  • Mskcc Therapeutic/Diagnostic Protocol
    Memorial Sloan Kettering Cancer Center IRB Number: 13-260 A(4) Approval date: 30-Mar-2018 MSKCC THERAPEUTIC/DIAGNOSTIC PROTOCOL Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma Principal Investigator/Department: Brian H. K ushner, MD Pediatrics Co-Principal Nai-Kong V. Cheung, MD, P hD Pediatrics Investigator(s)/Department: Investigator(s)/Department: Ellen M. Basu, MD, P hD Pediatrics Shakeel Modak, MD Pediatrics Stephen S. Roberts, MD Pediatrics Irina Ostrovnaya, P hD Epidemiology and Biostatistics Consenting Professional(s)/Department: Ellen M. Basu, MD, P hD Pediatrics Nai-Kong V. Cheung, MD, P hD Pediatrics Brian H. K ushner, MD Pediatrics Shakeel Modak, MD Pediatrics Stephen S. Roberts, MD Pediatrics Ple as e Note: A Consenting Profe ssional mus t have comple ted the mandatory Human Subje cts Education and Ce rtification Program. Memorial S loan-Kettering Cancer Center 1275 York Avenue New York, New York 10065 Page 1 of 25 Memorial Sloan Kettering Cancer Center IRB Number: 13-260 A(4) Approval date: 30-Mar-2018 Table of Contents 1.0 PROTOCOL SUMMARY AND/OR SCHEMA ....................................................................... 3 2.0 OB JECTIVES AND SCIENTIFIC AIMS ................................................................................ 4 3.0 BACKGROUND AND RATIONALE ...................................................................................... 4 4.0 OVERVIEW OF STUDY DESIGN/INTERVENTION ............................................................ 7 4.1 Design ..................................................................................................................................
    [Show full text]
  • Anti-GD2 Etoposide-Loaded Immunoliposomes for the Treatment of GD2 Positive Tumors
    The Texas Medical Center Library DigitalCommons@TMC The University of Texas MD Anderson Cancer Center UTHealth Graduate School of The University of Texas MD Anderson Cancer Biomedical Sciences Dissertations and Theses Center UTHealth Graduate School of (Open Access) Biomedical Sciences 5-2014 Anti-GD2 Etoposide-Loaded Immunoliposomes for the Treatment of GD2 Positive Tumors Brandon S. Brown Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations Part of the Amino Acids, Peptides, and Proteins Commons, Biological Factors Commons, Lipids Commons, Nanoscience and Nanotechnology Commons, and the Therapeutics Commons Recommended Citation Brown, Brandon S., "Anti-GD2 Etoposide-Loaded Immunoliposomes for the Treatment of GD2 Positive Tumors" (2014). The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access). 437. https://digitalcommons.library.tmc.edu/utgsbs_dissertations/437 This Dissertation (PhD) is brought to you for free and open access by the The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences at DigitalCommons@TMC. It has been accepted for inclusion in The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access) by an authorized administrator of DigitalCommons@TMC. For more information, please contact [email protected]. ANTI-GD2 ETOPOSIDE-LOADED IMMUNOLIPOSOMES FOR THE TREATMENT OF GD2 POSITIVE TUMORS by Brandon Scott Brown, B.S. APPROVED: ______________________________ Andrew Bean, Ph.D., Supervisory Professor ______________________________ Ennio Tasciotti, Ph.D., Supervisory Professor ______________________________ Diane Bick, Ph.D. ______________________________ Russell Broaddus, M.D., Ph.D. ______________________________ Neal Waxham, Ph.D. ______________________________ Jack Waymire, Ph.D.
    [Show full text]
  • Mechanism and Efficacy of a GD2-Specific Immunotherapy Using NK Cells
    Mechanism and efficacy of a GD2-specific immunotherapy using NK cells D i s s e r t a t i o n zur Erlangung des akademischen Grades d o c t o r r e r u m n a t u r a l i u m (Dr. rer. nat.) im Fach Biologie eingereicht an der Lebenswissenschaftlichen Fakultät der Humboldt-Universität zu Berlin von Diplom-Biochemikerin Diana Seidel Präsident der Humboldt-Universität zu Berlin Prof. Dr. Jan-Hendrik Olbertz Dekan der Lebenswissenschaftlichen Fakultät Prof. Dr. Richard Lucius Gutachter/innen: 1. Prof. Dr. Andreas Radbruch 2. Prof. Dr. Holger N. Lode 3. Prof. Dr. Hans-Dieter Volk Tag der mündlichen Prüfung: 13.02.2015 Table of contents Table of contents I Abbreviations IV 1. Introduction 1 1.1. Neuroblastoma 1 1.2. Treatment of neuroblastoma 1 1.3. Immunotherapy of neuroblastoma 2 1.4. Natural killer cells 8 1.5. NK-92 11 1.6. Chimeric antigen receptors 12 1.7. NK-92-scFv(ch14.18)-zeta 14 1.8. Aim of this study 15 2. Material and Methods 16 2.1. Material 16 2.1.1. Chemicals and supplements 16 2.1.2. Cell culture media und supplements 17 2.1.3. Special laboratory reagents and buffers 18 2.1.4. Kits 18 2.1.5. Antibodies 19 2.1.6. Cell culture media and buffers preparations 20 2.1.7. Special laboratory tools 22 2.1.8. Special laboratory equipment 22 2.1.9. Softwares 23 2.1.10. Cell lines 23 2.2. Methods 24 2.2.1.
    [Show full text]
  • Tumor-Associated Carbohydrates and Immunomodulatory Lectins As
    Open access Review J Immunother Cancer: first published as 10.1136/jitc-2020-001222 on 5 October 2020. Downloaded from Tumor- associated carbohydrates and immunomodulatory lectins as targets for cancer immunotherapy Natalia Rodrigues Mantuano, Marina Natoli , Alfred Zippelius , Heinz Läubli To cite: Rodrigues Mantuano N, ABSTRACT numerous biological functions.8–10 Cell Natoli M, Zippelius A, et al. During oncogenesis, tumor cells present specific surfaces and extracellular proteins are signifi- Tumor- associated carbohydrates carbohydrate chains that are new targets for cancer cantly glycosylated. In addition, glycosami- and immunomodulatory immunotherapy. Whereas these tumor-associa ted lectins as targets for cancer noglycans can be found in the extracellular carbohydrates (TACA) can be targeted with antibodies immunotherapy. Journal for matrix. Glycans are used as storage for energy ImmunoTherapy of Cancer and vaccination approaches, TACA including sialic acid- containing glycans are able to inhibit anticancer immune (glycogen), are structurally important (see 2020;8:e001222. doi:10.1136/ later for the stability of programmed cell jitc-2020-001222 responses by engagement of immune receptors on leukocytes. A family of immune-modula ting receptors death protein 1 (PD-1)) and can mediate NRM and MN contributed are sialic acid-binding Siglec receptors that have been signals. Whereas proteins undergo substan- equally. recently described to inhibit antitumor activity mediated tial post- translational modifications, in partic- by myeloid cells, natural killer cells and T cells. Other ular N- glycosylation and O- glycosylation,8–10 Accepted 28 August 2020 TACA-binding receptors including selectins have been intracellular modification of tyrosine with linked to cancer progression. Recent studies have shown 11 O- GlcNAc serves for intracellular signaling.
    [Show full text]
  • Ceramide Structure Predicts Tumor Ganglioside Immunosuppressive
    Proc. Nati. Acad. Sci. USA Vol. 91, pp. 1974-1978, March 1994 Medical Sciences Ceramide structure predicts tumor ganglioside immunosuppressive activity STEPHAN LADISCH*, RUIXIANG Li, AND ERIK OLSON Center for Cancer and Transplantation Biology, Children's National Medical Center, and Departments of Pediatrics and Biochemistry/Molecular Biology, George Washington University School of Medicine, Washington, DC 20010 Communicated by George J. Todaro, November 15, 1993 ABSTRACT Molecular determinants of biological activity MATERIALS AND METHODS of lioides are generally believed to be carbohydrate in nature. However, our stuies of immunomodulation by highly Gangioside Purification. Total gangliosides were purified purified naturally occurring tumor ganglosides provide an- from normal human brain and from human and munne tumor other perspective: while the Immunosuppressive activity of cells by a sequence of steps including extraction of the cells gallosldes requires the intact molecule (both carbohydrate with chloroform/methanol, 1:1 (vol/vol), partition of the and ceramide moieties), ceramide strcue siny influ- total lipid extract in diisopropyl ether/1-butanol (21), and ences gangliode Imm osuppressive activity. Molecular spe- Sephadex G-50 gel filtration of the ganglioside-containing cds of human neuroblastoma GD2 galloslde in which the aqueous phase. ceramide contains a shorter fatty acyl chain (C16:0, C18:0) HPLC. Individual gangliosides were separated and purified were 6- to 10-fold more active than those with a longer fatty by HPLC methods ofGazzotti et al. (22, 23). Briefly, 600-800 acyl chain (C22:0/C24:1, C24:0). These indings were con- nmol of lipid-bound sialic acid of total gangliosides was firmed in studies of ceramide specie of human leukemia dissolved in 100 y1 of water and chromatographed using the sialosylparagloboside and murine lymph a Ga1NAcGM1b.
    [Show full text]
  • Ganglioside GM2 As a Human Tumor Antigen (OFA-I-1) (Monospecific Human Antitumor Antibody/Membrane Glycolipid/Fetal Brain/Melanoma) TADASHI TAI*, JAMES C
    Proc. Natl. Acad. Sci. USA Vol. 80, pp. 5392-5396, September 1983 Immunology Ganglioside GM2 as a human tumor antigen (OFA-I-1) (monospecific human antitumor antibody/membrane glycolipid/fetal brain/melanoma) TADASHI TAI*, JAMES C. PAULSONt, LESLIE D. CAHANt, AND REIKO F. IRIE*§ Departments of *Surgery/Oncology, tBiological Chemistry, and tSurgery/Neurosurgerv, University of California, Los Angeles, School of Medicine, Los Angeles, California 90024 Communicated by S. Hagiwara, May 23, 1983 ABSTRACT A monospecific antibody produced in vitro by a chemical nature of OFA-I-1 that binds to monospecific anti- B-lymphoblastoid cell line transformed with Epstein-Barr virus body OFA-I-1 produced in vitro. By using immune adherence has been shown to recognize a membrane antigen (OFA-I-1) on inhibition as the assay, the antigen was successfully purified human tumors and fetal brain. This study identifies the chemical and characterized as the ganglioside GM2. nature of OFA-I-1. The glycolipid fraction of antigen-rich spent medium of an OFA-I-1-positive melanoma cell line, M14, was ex- tracted by chloroform/methanol/water, 4:8:3 (vol/vol), and was MATERIALS AND METHODS separated into fractions of neutral glycolipids and gangliosides by OFA-I-1 Antigen Source. A human melanomacell line, UCLA- DEAE-Sephadex followed by base treatment and Bio-sil A column SO-M14 (M14), which expresses OFA-I-1 and OFA-I-2 and sheds elution. OFA-I-1 antigens were found exclusively in the ganglio- both antigens into the culture medium, was maintained in a side fraction when assayed with monospecific anti-OFA-I-1 by an chemically defined medium supplemented with 0.05% human immune adherence inhibition test.
    [Show full text]